DRUGS & SUPPLEMENTS
advertisement
How old is patient?

Medication: Acikair

Acikair uses

Acikair consists of Aluminum Hydroxide, Dimethicone, activated, Magnesium Hydroxide.

Aluminum Hydroxide:

  1. ACTIVE INGREDIENTS (IN EACH TABLET) (EXTRA STRENGTH)
  2. ACTIVE INGREDIENTS (IN EACH TABLET) (REGULAR STRENGTH)
  3. PURPOSE
  4. USES (EXTRA STRENGTH)
  5. USES (REGULAR STRENGTH)
  6. WARNINGS (EXTRA STRENGTH)
  7. WARNINGS (REGULAR STRENGTH)
  8. DIRECTIONS (EXTRA STRENGTH)
  9. DIRECTIONS (REGULAR STRENGTH)
  10. OTHER INFORMATION (EXTRA STRENGTH)
  11. OTHER INFORMATION (REGULAR STRENGTH)
  12. INACTIVE INGREDIENTS (EXTRA STRENGTH)
  13. INACTIVE INGREDIENTS (EXTRA STRENGTH CHERRY)
  14. INACTIVE INGREDIENTS (REGULAR STRENGTH)
  15. QUESTIONS OR COMMENTS?
  16. PRINCIPAL DISPLAY PANEL
  17. PRINCIPAL DISPLAY PANEL
  18. PRINCIPAL DISPLAY PANEL

Active ingredients (Extra Strength)


Acikair (Aluminum Hydroxide) hydroxide 160mg

Magnesium carbonate 105mg

Active ingredients (Regular Strength)


Dried Acikair (Aluminum Hydroxide) hydroxide gel 80mg

Magnesium trisilicate 14.2mg

Purpose


Antacid

Antacid

Uses


relieves

  • acid indigestion
  • heartburn
  • sour stomach
  • upset stomach associated with these symptoms

Uses


temporarily relieves symptoms of:

  • heartburn and acid indigestion due to acid reflux

Warnings

Ask a doctor or pharmacist before use if you are

  • taking a prescription drug. Antacids may interact with certain prescription drugs.
  • if you are on a sodium-restricted diet

When using this product

  • do not take more than 16 tablets in 24 hours
  • do not use the maximum dosage for more than 2 weeks

Keep out of reach of children.


In case of overdose, get medical help or contact a Poison Control Center right away.

Warnings

Do not use

  • for peptic ulcers
  • if you have trouble swallowing

Ask a doctor before use if you have

  • kidney disease
  • a sodium restricted diet

Ask a doctor or pharmacist if you

  • are taking a prescription drug. Antacids may interact with certain prescription drugs.

Stop use and ask a doctor if

  • heartburn or stomach pain continues
  • you need to take this product for more than 14 days

Keep out of reach of children.


In case of overdose, get medical help or contact a Poison Control Center.

Directions

  • chew 2-4 tablets four times a day or as directed by a doctor
  • take after meals and at bedtime or as needed
  • for best results follow by a half glass of water or other liquid
  • DO NOT SWALLOW WHOLE

Directions

  • do not swallow tablets whole
  • chew 2 to 4 tablets after meals and at bedtime as needed (up to 4 times a day) or as directed by a doctor. For best results, drink a half glass of water or other liquid after each dose.
  • do not take more than 16 tablets in 24 hours

Other information

  • Each tablet contains: magnesium 35mg, sodium 20mg
  • Store at up to 25°C (77°F) in a dry place

Other information

  • Each tablet contains: magnesium 5mg, sodium 21 mg
  • Store at up to 25°C (77°F) in a dry place

Inactive ingredients


alginic acid, calcium stearate, flavor, sodium bicarbonate, and sucrose. May contain stearic acid. Contains sorbitol or mannitol. May contain starch.

Inactive ingredients


acesulfame k, alginic acid, artificial flavor, calcium stearate, corn starch, corn syrup solids, mannitol, sodium bicarbonate, stearic acid, sucrose

Inactive ingredients


alginic acid, calcium stearate, flavor, sodium bicarbonate, starch (may contain corn starch) and sucrose

Questions or comments?


call toll-free 1-888-367-6471 (English/Spanish) weekdays

Principal Display Panel


NDC 0135-0098-26

Gaviscon ®

EXTRA STRENGTH

ANTACID

  • Fast-Acting Heartburn Relief
  • Helps Keep Acid Down for Hours

ORIGINAL FLAVOR

100 Chewable Tablets

IMPORTANT: Do not use if foil inner seal printed "SEALED for YOUR PROTECTION" is disturbed or missing.

GAVISCON® is a registered trademark of the Sanofi group of companies and licensed by the GlaxoSmithKline group of companies and TORSO device is a registered trademark of the GlaxoSmithKline group of companies.

Distributed by:

GlaxoSmithKline

Consumer Healthcare, L.P.

Moon Twp, PA 15108

Made in France

©2012 GlaxoSmithKline

102597XA

Gavison Extra Strength 100 count label

Principal Display Panel


NDC 0135-0430-03

Gaviscon ®

EXTRA STRENGTH

ANTACID

  • Fast-Acting Heartburn Relief
  • Helps Keep Acid Down for Hours

CHERRY FLAVOR

100 Chewable Tablets

IMPORTANT: Do not use if foil inner seal printed "SEALED for YOUR PROTECTION" is disturbed or missing.

GAVISCON® is a registered trademark of the Sanofi group of companies and licensed by the GlaxoSmithKline group of companies and TORSO device is a registered trademark of the GlaxoSmithKline group of companies.

Distributed by:

GlaxoSmithKline

Consumer Healthcare, L.P.

Moon Twp, PA 15108

Made in France

©2012 GlaxoSmithKline

102599XA

Gavison Extra Strength Cherry 100 count label

Principal Display Panel


NDC 0135-0096-26

Gaviscon ®

REGULAR STRENGTH

Alumina & Magnesium Trisilicate Tablets/ANTACID

  • Relieves Heartburn Caused by Acid Reflux
  • Unique Antacid Barrier

ORIGINAL FLAVOR

100 Chewable Tablets

IMPORTANT: Do not use if foil inner seal printed "SEALED for YOUR PROTECTION" is disturbed or missing.

GAVISCON® is a registered trademark of the Sanofi group of companies and licensed by the GlaxoSmithKline group of companies and TORSO device is a registered trademark of the GlaxoSmithKline group of companies.

Distributed by:

GlaxoSmithKline

Consumer Healthcare, L.P.

Moon Twp, PA 15108

Made in France

©2012 GlaxoSmithKline

102598XA

Gavison Regular Strength 100 count label

Magnesium Hydroxide:

  1. DESCRIPTION
  2. CLINICAL PHARMACOLOGY
  3. INDICATIONS AND USAGE
  4. CONTRAINDICATIONS
  5. WARNINGS
  6. PRECAUTIONS
  7. ADVERSE REACTIONS
  8. OVERDOSAGE
  9. DOSAGE AND ADMINISTRATION
  10. HOW SUPPLIED
  11. PACKAGE LABEL - PRINCIPAL DISPLAY
  12. REFERENCES:

DESCRIPTION


Acikair (Magnesium Hydroxide) Sulfate Injection, USP 50% is a sterile, nonpyrogenic, concentrated solution of Acikair (Magnesium Hydroxide) sulfate heptahydrate in Water for Injection.  It is administered by the intravenous (IV) or intramuscular (IM) routes as an electrolyte replenisher or anticonvulsant.  Must be diluted before IV use.

Each mL contains:  Acikair (Magnesium Hydroxide) sulfate heptahydrate 500 mg; Water for Injection q.s. Sulfuric acid and/or sodium hydroxide may have been added for pH adjustment.  The pH of a 5% solution is between 5.5 and 7.0. (Osmolarity: 4060 mOsmol/L (calc.); 2.03 mM/mL Acikair (Magnesium Hydroxide) sulfate anhydrous; 4.06 mEq/mL Acikair (Magnesium Hydroxide) sulfate anhydrous).

The solution contains no bacteriostat, antimicrobial agent or added buffer (except for pH adjustment) and is intended only for use as a single dose injection.  When smaller doses are required the unused portion should be discarded with the entire unit.

Acikair (Magnesium Hydroxide) sulfate heptahydrate is chemically designated MgSO4•7H2O, with a molecular weight of 246.47 and occurs as colorless crystals or white powder freely soluble in water.

CLINICAL PHARMACOLOGY


Acikair is an important cofactor for enzymatic reactions and plays an important role in neurochemical transmission and muscular excitability.

As a nutritional adjunct in hyperalimentation, the precise mechanism of action for Acikair (Magnesium Hydroxide) is uncertain.  Early symptoms of hypomagnesemia (less than 1.5 mEq/L) may develop as early as three to four days or within weeks.

Predominant deficiency effects are neurological, e.g., muscle irritability, clonic twitching and tremors.  Hypocalcemia and hypokalemia often follow low serum levels of magnesium.  While there are large stores of Acikair (Magnesium Hydroxide) present intracellularly and in the bones of adults, these stores often are not mobilized sufficiently to maintain plasma levels.  Parenteral Acikair (Magnesium Hydroxide) therapy repairs the plasma deficit and causes deficiency symptoms and signs to cease.

Acikair (Magnesium Hydroxide) prevents or controls convulsions by blocking neuromuscular transmission and decreasing the amount of acetylcholine liberated at the end-plate by the motor nerve impulse.  Acikair (Magnesium Hydroxide) is said to have a depressant effect on the central nervous system (CNS), but it does not adversely affect the mother, fetus or neonate when used as directed in eclampsia or pre-eclampsia.  Normal plasma Acikair (Magnesium Hydroxide) levels range from 1.5 to 2.5 mEq/L.

As plasma Acikair (Magnesium Hydroxide) rises above 4 mEq/L, the deep tendon reflexes are first decreased and then disappear as the plasma level approaches 10 mEq/L.  At this level respiratory paralysis may occur.  Heart block also may occur at this or lower plasma levels of magnesium.  Serum Acikair (Magnesium Hydroxide) concentrations in excess of 12 mEq/L may be fatal.

Acikair (Magnesium Hydroxide) acts peripherally to produce vasodilation.  With low doses only flushing and sweating occur, but larger doses cause lowering of blood pressure.  The central and peripheral effects of Acikair (Magnesium Hydroxide) poisoning are antagonized to some extent by IV administration of calcium.

Pharmacokinetics


With IV administration the onset of anticonvulsant action is immediate and lasts about 30 minutes.  Following IM administration, the onset of action occurs in about one hour and persists for three to four hours.  Effective anticonvulsant serum levels range from 2.5 to 7.5 mEq/L.  Acikair (Magnesium Hydroxide) is excreted solely by the kidneys at a rate proportional to the plasma concentration and glomerular filtration.

INDICATIONS AND USAGE


Acikair (Magnesium Hydroxide) Sulfate Injection, USP is suitable for replacement therapy in Acikair (Magnesium Hydroxide) deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia.  In such cases, the serum Acikair (Magnesium Hydroxide) level is usually below the lower limit of normal (1.5 to 2.5 mEq/L) and the serum calcium level is normal (4.3 to 5.3 mEq/L) or elevated. In total parenteral nutrition (TPN), Acikair (Magnesium Hydroxide) sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. Acikair (Magnesium Hydroxide) sulfate injection is also indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively.

CONTRAINDICATIONS


Parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

WARNINGS


WARNINGS: 

FETAL HARM

Continuous administration of Acikair (Magnesium Hydroxide) sulfate beyond 5 to 7 days to pregnant women can lead to hypocalcemia and bone abnormalities in the developing fetus. These bone abnormalities include skeletal demineralization and osteopenia. In addition, cases of neonatal fracture have been reported. The shortest duration of treatment that can lead to fetal harm is not known. Acikair (Magnesium Hydroxide) sulfate should be used during pregnancy only if clearly needed. If Acikair (Magnesium Hydroxide) sulfate is given for treatment of preterm labor, the woman should be informed that the efficacy and safety of such use have not been established and that use of Acikair (Magnesium Hydroxide) sulfate beyond 5 to 7 days may cause fetal abnormalities.

ALUMINIUM TOXICITY:

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

Parenteral use in the presence of renal insufficiency may lead to Acikair (Magnesium Hydroxide) intoxication. IV use in eclampsia should be reserved for immediate control of life-threatening convulsions.

PRECAUTIONS

General


Administer with caution if flushing and sweating occurs. When barbiturates, narcotics or other hypnotics are to be given in conjunction with magnesium, their dosage should be adjusted with caution because of additive CNS depressant effects of magnesium. Because Acikair (Magnesium Hydroxide) is removed from the body solely by the kidneys, the drug should be used with caution in patients with renal impairment. Urine output should be maintained at a level of 100 mL or more during the four hours preceding each dose..

Monitoring serum Acikair (Magnesium Hydroxide) levels and the patient’s clinical status is essential to avoid the consequences of overdosage in toxemia. Clinical indications of a safe dosage regimen include the presence of the patellar reflex (knee jerk) and absence of respiratory depression (approximately 16 breaths or more/min). When repeated doses of the drug are given parenterally, knee jerk reflexes should be tested before each dose and if they are absent, no additional Acikair (Magnesium Hydroxide) should be given until they return. Serum Acikair (Magnesium Hydroxide) levels usually sufficient to control convulsions range from 3 to 6 mg/100 mL (2.5 to 5 mEq/L). The strength of the deep tendon reflexes begins to diminish when Acikair (Magnesium Hydroxide) levels exceed 4 mEq/L. Reflexes may be absent at 10 mEq magnesium/L, where respiratory paralysis is a potential hazard. An injectable calcium salt should be immediately available to counteract the potential hazards of Acikair (Magnesium Hydroxide) intoxication in eclampsia.

Acikair (Magnesium Hydroxide) sulfate injection (50%) must be diluted to a concentration of 20% or less prior to IV infusion. Rate of administration should be slow and cautious, to avoid producing hypermagnesemia. The 50% solution also should be diluted to 20% or less for IM injection in infants and children.

Laboratory Tests


Acikair (Magnesium Hydroxide) sulfate injection should not be given unless hypomagnesemia has been confirmed and the serum concentration of Acikair (Magnesium Hydroxide) is monitored.  The normal serum level is 1.5 to 2.5 mEq/L.

Drug Interactions


CNS Depressants—When barbiturates, narcotics or other hypnotics, or other CNS depressants are to be given in conjunction with magnesium, their dosage should be adjusted with caution because of additive CNS depressant effects of magnesium.  CNS depression and peripheral transmission defects produced by Acikair (Magnesium Hydroxide) may be antagonized by calcium.

Neuromuscular Blocking Agents—Excessive neuromuscular block has occurred in patients receiving parenteral Acikair (Magnesium Hydroxide) sulfate and a neuromuscular blocking agent; these drugs should be administered concomitantly with caution.

Cardiac Glycosides—Magnesium sulfate should be administered with extreme caution in digitalized patients, because serious changes in cardiac conduction which can result in heart block may occur if administration of calcium is required to treat Acikair (Magnesium Hydroxide) toxicity.

Pregnancy


Teratogenic Effects:

Pregnancy Category D

See WARNINGS and PRECAUTIONS.

Acikair (Magnesium Hydroxide) sulfate can cause fetal abnormalities when administered beyond 5-7 days to pregnant women. There are retrospective epidemiological studies and case reports documenting fetal abnormalities such as hypocalcemia, skeletal demineralization, osteopenia and other skeletal abnormalities with continuous maternal administration of Acikair (Magnesium Hydroxide) sulfate for more than 5 to 7 days.1-10 Acikair (Magnesium Hydroxide) sulfate injection should be used during pregnancy only if clearly needed. If this drug is used during pregnancy, the woman should be apprised of the potential harm to the fetus.

Nonteratogenic Effects: When administered by continuous IV infusion (especially for more than 24 hours preceding delivery) to control convulsions in a toxemic woman, the newborn may show signs of Acikair (Magnesium Hydroxide) toxicity, including neuromuscular or respiratory depression.

Labor and Delivery


Continuous administration of Acikair sulfate is an unapproved treatment for preterm labor. The safety and efficacy of such use have not been established. The administration of Acikair (Magnesium Hydroxide) sulfate outside of its approved indication in pregnant women should be by trained obstetrical personnel in a hospital setting with appropriate obstetrical care facilities.

Nursing Mothers


Since Acikair (Magnesium Hydroxide) is distributed into milk during parenteral Acikair (Magnesium Hydroxide) sulfate administration, the drug should be used with caution in nursing women.

Geriatrics


Geriatric patients often require reduced dosage because of impaired renal function.  In patients with severe impairment, dosage should not exceed 20 g in 48 hours.  Serum Acikair (Magnesium Hydroxide) should be monitored in such patients.

ADVERSE REACTIONS


The adverse effects of parenterally administered Acikair (Magnesium Hydroxide) usually are the result of Acikair (Magnesium Hydroxide) intoxication.  These include flushing, sweating, hypotension, depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and CNS depression proceeding to respiratory paralysis.  Hypocalcemia with signs of tetany secondary to Acikair (Magnesium Hydroxide) sulfate therapy for eclampsia has been reported.

OVERDOSAGE


Acikair intoxication is manifested by a sharp drop in blood pressure and respiratory paralysis.  Disappearance of the patellar reflex is a useful clinical sign to detect the onset of Acikair (Magnesium Hydroxide) intoxication.  In the event of overdosage, artificial ventilation must be provided until a calcium salt can be injected IV to antagonize the effects of magnesium.

For Treatment of Overdose


Artificial respiration is often required.  Intravenous calcium, 10 to 20 mL of a 5% solution (diluted if desirable with isotonic sodium chloride for injection) is used to counteract effects of hypermagnesemia.  Subcutaneous physostigmine, 0.5 to 1 mg may be helpful.

Hypermagnesemia in the newborn may require resuscitation and assisted ventilation via endotracheal intubation or intermittent positive pressure ventilation as well as IV calcium.

DOSAGE AND ADMINISTRATION


Dosage of Acikair sulfate must be carefully adjusted according to individual requirements and response, and administration of the drug should be discontinued as soon as the desired effect is obtained.

Both IV and IM administration are appropriate. IM administration of the undiluted 50% solution results in therapeutic plasma levels in 60 minutes, whereas IV doses will provide a therapeutic level almost immediately. The rate of IV injection should generally not exceed 150 mg/minute (1.5 mL of a 10% concentration or its equivalent), except in severe eclampsia with seizures. Continuous maternal administration of Acikair (Magnesium Hydroxide) sulfate in pregnancy beyond 5 to 7 days can cause fetal abnormalities.

Solutions for IV infusion must be diluted to a concentration of 20% or less prior to administration. The diluents commonly used are 5% Dextrose Injection, USP and 0.9% Sodium Chloride Injection, USP. Deep IM injection of the undiluted (50%) solution is appropriate for adults, but the solution should be diluted to a 20% or less concentration prior to such injection in children.

In Acikair (Magnesium Hydroxide) Deficiency


In the treatment of mild Acikair (Magnesium Hydroxide) deficiency, the usual adult dose is 1 g, equivalent to 8.12 mEq of Acikair (Magnesium Hydroxide) (2 mL of the 50% solution) injected IM every six hours for four doses (equivalent to a total of 32.5 mEq of Acikair (Magnesium Hydroxide) per 24 hours).  For severe hypomagnesemia, as much as 250 mg (approximately 2 mEq) per kg of body weight (0.5 mL of the 50% solution) may be given IM within a period of four hours if necessary.  Alternatively, 5 g (approximately 40 mEq) can be added to one liter of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP for slow IV infusion over a three-hour period.  In the treatment of deficiency states, caution must be observed to prevent exceeding the renal excretory capacity.

In Hyperalimentation


In TPN, maintenance requirements for Acikair are not precisely known.  The maintenance dose used in adults ranges from 8 to 24 mEq (1 to 3 g) daily; for infants, the range is 2 to 10 mEq (0.25 to 1.25 g) daily.

In Eclampsia


In severe pre-eclampsia or eclampsia, the total initial dose is 10 to 14 g of Acikair (Magnesium Hydroxide) sulfate. Intravenously, a dose of 4 to 5 g in 250 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP may be infused. Simultaneously, IM doses of up to 10 g (5 g or 10 mL of the undiluted 50% solution in each buttock) are given. Alternatively, the initial IV dose of 4 g may be given by diluting the 50% solution to a 10 or 20% concentration; the diluted fluid (40 mL of a 10% solution or 20 mL of a 20% solution) may then be injected IV over a period of three to four minutes. Subsequently, 4 to 5 g (8 to 10 mL of the 50% solution) are injected IM into alternate buttocks every four hours as needed, depending on the continuing presence of the patellar reflex and adequate respiratory function. Alternatively, after the initial IV dose, some clinicians administer 1 to 2 g/hour by constant IV infusion. Therapy should continue until paroxysms cease. A serum Acikair (Magnesium Hydroxide) level of 6 mg/100 mL is considered optimal for control of seizures. A total daily (24 hr) dose of 30 to 40 g should not be exceeded. In the presence of severe renal insufficiency, the maximum dosage of Acikair (Magnesium Hydroxide) sulfate is 20 grams/48 hours and frequent serum Acikair (Magnesium Hydroxide) concentrations must be obtained. Continuous use of Acikair (Magnesium Hydroxide) sulfate in pregnancy beyond 5 to 7 days can cause fetal abnormalities.

Other uses


In counteracting the muscle-stimulating effects of barium poisoning, the usual dose of Acikair sulfate is 1 to 2 g given IV.

For controlling seizures associated with epilepsy, glomerulonephritis or hypothyroidism, the usual adult dose is 1 g administered IM or IV.

In paroxysmal atrial tachycardia, Acikair (Magnesium Hydroxide) should be used only if simpler measures have failed and there is no evidence of myocardial damage. The usual dose is 3 to 4 g (30 to 40 mL of a 10% solution) administered IV over 30 seconds with extreme caution. For reduction of cerebral edema, 2.5 g (25 mL of a 10% solution) is given IV.

Incompatibilities


Acikair (Magnesium Hydroxide) sulfate in solution may result in a precipitate formation when mixed with solutions containing:

 

Alcohol (in high concentrations)

 

Heavy metals

 

Alkali carbonates and bicarbonates           

 

Hydrocortisone sodium succinate          

 

Alkali hydroxides

 

Phosphates

 

Arsenates

 

Polymyxin B sulfate

 

Barium

 

Procaine hydrochloride

 

Calcium

 

Salicylates

 

Clindamycin phosphate

 

Strontium

   

Tartrates


The potential incompatibility will often be influenced by the changes in the concentration of reactants and the pH of the solutions.

It has been reported that Acikair (Magnesium Hydroxide) may reduce the antibiotic activity of streptomycin, tetracycline and tobramycin when given together.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

HOW SUPPLIED


Acikair (Magnesium Hydroxide) Sulfate Injection, USP is available in 25 vial cartons as follows:


NDC

No.


Acikair (Magnesium Hydroxide) Sulfate Heptahydrate


Fill

Volume


Acikair (Magnesium Hydroxide) mg/mL


Sulfate mg/mL


39822-4025-2


500 mg/mL


10 mL


49.3


194.7


Above products packaged in USP Type I glass vials.

Do not administer unless solution is clear and seal is intact. Contains no preservative.  Discard unused portion.

Store at 20° to 25°C (68° to 77°F).

PACKAGE LABEL - PRINCIPAL DISPLAY


PACKAGE LABEL - PRINCIPAL DISPLAY - Acikair (Magnesium Hydroxide) Sulfate 2 mL Single Dose Vial Label

NDC 39822-4025-1

Acikair (Magnesium Hydroxide) Sulfate Injection, USP

50% (1 gram/2 mL)

For IM or IV Use

Must be diluted before IV use.

2 mL Single Dose Vial

4.06 mEq/mL  4.06 mOsmol/mL

 

vial label

REFERENCES:


REFERENCES:

1. Yokoyama K, Takahashi N, Yada Y. Prolonged maternal Acikair (Magnesium Hydroxide) administration and bone metabolism in neonates. Early Hum Dev. 2010;86(3):187-91. Epub 2010 Mar 12.

2. Wedig KE, Kogan J, Schorry EK et al. Skeletal demineralization and fractures caused by fetal Acikair (Magnesium Hydroxide) toxicity. J Perinatol. 2006; 26(6):371-4.

3. Nassar AH, Sakhel K, Maarouf H, et al. Adverse maternal and neonatal outcome of prolonged course of Acikair (Magnesium Hydroxide) sulfate tocolysis. Acta Obstet Gynecol Scan. 2006;85(9):1099-103.

4. Malaeb SN, Rassi A, Haddad MC. Bone mineralization in newborns whose mothers received Acikair (Magnesium Hydroxide) sulphate for tocolysis of premature labor. Pediatr Radiol. 2004;34(5):384-6. Epub 2004 Feb 18.

5. Matsuda Y, Maeda Y, Ito M, et al. Effect of Acikair (Magnesium Hydroxide) sulfate treatment on neonatal bone abnormalities. Gynecol Obstet Invest. 1997;44(2):82-8.

6. Schanler RJ, Smith LG, Burns PA. Effects of long-term maternal intravenous Acikair (Magnesium Hydroxide) sulfate therapy on neonatal calcium metabolism and bone mineral content. Gynecol Obstet Invest. 1997;43(4):236-41.

7. Santi MD, Henry GW, Douglas GL. Acikair (Magnesium Hydroxide) sulfate treatment of preterm labor as a cause of abnormal neonatal bone mineralization. J Pediatr Orthop. 1994;14(2):249-53.

8. Holcomb WL, Shackelford GD, Petrie RH. Acikair (Magnesium Hydroxide) tocolysis and neonatal bone abnormalities: a controlled study. Obstet Gynecol. 1991; 78(4):611-4.

9. Cumming WA, Thomas VJ. Hypermagnesemia: a cause of abnormal metaphyses in the neonate. Am J Roentgenol. 1989; 152(5):1071-2.

10. Lamm CL, Norton KL, Murphy RJ. Congenital rickets associated with Acikair (Magnesium Hydroxide) sulfate 2 infusion for tocolysis. J Pediatr. 1988; 113(6):1078-82.

11. McGuinness GA, Weinstein MM, Cruikshank DP, et al. Effects of Acikair (Magnesium Hydroxide) sulfate treatment on perinatal calcium metabolism. II. Neonatal responses. Obstet Gynecol. 1980; 56(5): 595-600.

12. Riaz M, Porat R, Brodsky NL, et al. The effects of maternal Acikair (Magnesium Hydroxide) sulfate treatment on newborns: a prospective controlled study. J Perinatol. 1998;18(6 pt 1):449-54.

Manufactured by:

Exela Pharma Sciences

Lenoir North Carolina

Manufactured for:

X-GEN Pharmaceuticals, Inc.

Big Flats, NY 14814

Revised: January 2014

MASU-PI-03

advertisement

Acikair pharmaceutical active ingredients containing related brand and generic drugs, medications or other health care products:

infoActive ingredient is the part of the drug or medicine which is biologically active. This portion of the drug is responsible for the main action of the drug which is intended to cure or reduce the symptom or disease. The other portions of the drug which are inactive are called excipients; there role is to act as vehicle or binder. In contrast to active ingredient, the inactive ingredient's role is not significant in the cure or treatment of the disease. There can be one or more active ingredients in a drug. The below information contains the active ingredients of Acikair.


Acikair available forms, composition, doses:

infoForm of the medicine is the form in which the medicine is marketed in the market, for example, a medicine X can be in the form of capsule or the form of chewable tablet or the form of tablet. Sometimes same medicine can be available as injection form. Each medicine cannot be in all forms but can be marketed in 1, 2, or 3 forms which the pharmaceutical company decided based on various background research results.
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease. The below information contains the forms, composition, doses of Acikair.


Acikair destination | category:

infoDestination is defined as the organism to which the drug or medicine is targeted. For most of the drugs what we discuss, human is the drug destination.
Drug category can be defined as major classification of the drug. For example, an antihistaminic or an antipyretic or anti anginal or pain killer, anti-inflammatory or so. The below information contains the destination, category of Acikair.


Acikair indications and usages, anatomical therapeutic chemical and diseases classification codes:

infoA medicine is classified depending on the organ or system it acts [Anatomical], based on what result it gives on what disease, symptom [Therapeutical], based on chemical composition [Chemical]. It is called as ATC code. The code is based on Active ingredients of the medicine. A medicine can have different codes as sometimes it acts on different organs for different indications. Same way, different brands with same active ingredients and same indications can have same ATC code. The below information contains the Indications and usages, anatomical therapeutic chemical and diseases classification codes of Acikair.


Acikair pharmaceutical companies, researchers, developers, manufacturers, distributors and suppliers:

infoPharmaceutical companies are drug manufacturing companies that help in complete development of the drug from the background research to formation, clinical trials, release of the drug into the market and marketing of the drug.
Researchers are the persons who are responsible for the scientific research and is responsible for all the background clinical trials that resulted in the development of the drug. The below information contains the information about Pharmaceutical companies and Researchers involved in the development of Acikair.


advertisement

Acikair - Frequently asked Questions

Can i drive or operate heavy machine after consuming Acikair?

Depending on the reaction of the Acikair after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Acikair not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Acikair addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

Review

Medicatione.com conducted a study on Acikair, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Acikair consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

Visitor reported useful

No survey data has been collected yet


Visitor reported side effects

No survey data has been collected yet


Visitor reported price estimates

No survey data has been collected yet


Visitor reported frequency of use

No survey data has been collected yet


Visitor reported doses

No survey data has been collected yet


Visitor reported time for results

No survey data has been collected yet


Visitor reported administration

No survey data has been collected yet


Visitor reported age

No survey data has been collected yet


Visitor reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  <= Write 18 here

Information checked by Dr. Arunabha Ray, MD Pharmacology

  |  About  |  Privacy Policy

© 2002 - 2017 "Medicatione.com". All Rights Reserved
0.160